Abstract: The present disclosure relates to relates to systems and methods for on-demand delivery of a therapeutic agent from an eye mounted device. Particularly, aspects of the present invention are directed to a method of delivering a therapeutic agent, the method including receiving, at a controller of a therapeutic agent release and delivery device, a first command signal for delivery of a therapeutic agent based on a dosing time window. Upon receipt of the first command signal, the controller determines whether one or more compliance conditions are satisfied. When the one or more conditions are satisfied, the controller initiate a release and delivery protocol that commands a signal generator to generate and send a second command signal causing a capacitor or one or more circuits to deliver an actuation signal causing one or more therapeutic agent delivery mechanisms to open and release the therapeutic agent from one or more reservoirs.

Abstract: An active drug dispensing ophthalmic device can include a plurality of drug reservoirs, each covered by an electrode, and a controller-responder architecture. Electrodissolution of each electrode and the associated drug release can be governed by a controller via a responder. Employing a controller-responder architecture can reduce the number of connections and separate electrical signals required to actively dispense drugs from each of the plurality of drug reservoirs. The controller can be connected to a plurality of responders via a control line bundle and each of the plurality of responders can deliver signals to the electrode(s) covering a portion of a plurality of drug reservoirs. The controller-responder architecture can also employ a composite electrical communication signal to even further decrease the number of electrical connections required from a controller to each of the responders.

Abstract: The present disclosure relates to devices and systems for targeted and controlled delivery of a therapeutic agent to a treatment site of an eye. Particularly, aspects are directed to a therapeutic agent delivery device that includes a polymeric substrate having a release region, a delivery region, and a receiving region; one or more reservoirs formed within the release region; a therapeutic agent disposed within the one or more reservoirs; an active, passive, or combination thereof controlled release mechanism for release of the therapeutic agent from the one or more reservoirs into the delivery region; and a circuit formed on the polymeric substrate, the circuit having a current source, a first iontophoresis electrode located within the delivery region for transport of the therapeutic agent from the delivery region into a target tissue via electromigration, and a second iontophoresis electrode located within the receiving region for maintaining electroneutrality within the tissue.

Abstract: Uniform and location patterned drug release can be achieved via microchannel(s) embedded in a drug dispensing ophthalmic device. At least one reservoir can be encapsulated within the ophthalmic device at a discrete location to hold an amount of a drug. Each reservoir can be covered by an electrode that electrodissolves to release the drug. At least one microchannel having a length and holding at least water is encapsulated in the ophthalmic device between the reservoir and the side of the ophthalmic device facing the eye. After release from the reservoir, the drug spreads through an entirety of the length of the microchannel due to a capillary force inside the microchannel and a diffusion coefficient of the drug in the water. The amount of the drug diffuses from a plurality of locations along the entirety of the length of the microchannel.

Abstract: A drug dispensing ophthalmic device can be constructed from integrated modular elements. First, an integrated device can be created by mating an interconnect interface of an electronic control module (ECM) to a passive interconnect interface of a primary drug container module (PDCM) and forming an electrical connection between the interconnect interface of the ECM to the passive interconnect interface of the PDCM. Then, the integrated device can be encapsulated within a body of an ophthalmic device.

Abstract: Systems, eye-mountable devices, and methods that facilitate chronotherapeutic treatment of primary open-angle glaucoma are provided which enable therapeutic products to be delivered to the eye in a controlled manner only when desired. According to one embodiment, an eye-mountable device comprises a substrate having an eye-mounting surface for positioning on an eye of a patient, a sensor that obtains a plurality of measurements representative of a condition of the eye of the patient over a period of time, a therapeutic agent delivery assembly coupled, and a processor for executing a temporal model of a therapeutic agent delivery in communication with the sensor and the therapeutic agent delivery assembly. The processor receives the plurality of measurements and activates the therapeutic agent delivery assembly to administer a first amount of a drug to the eye of the patient based on the temporal model associated with the plurality of measurements.

Abstract: A dry eye treatment device includes a substrate. At least one reservoir is formed in the substrate. A histamine agonist is disposed within the at least one reservoir. The histamine agonist is configured to be delivered to at least one histamine receptor on or adjacent to an eye.

Abstract: A periocular ring configured to be worn on an eye of a user that includes a plurality of electrodes spaced along the periocular ring; a microcontroller; and a lead assembly extending along at least a portion of the periocular ring; wherein the lead assembly extends between the microcontroller and the plurality of electrodes to operably couple the plurality of electrodes to the microcontroller; and wherein the microcontroller is configured to activate the plurality of electrodes via the lead assembly to stimulate a lacrimal gland of the user. The periocular ring has an opening that defines an innermost diameter; and wherein, when the periocular ring is worn on the eye of the user, a portion of the eye extends through the opening of the periocular ring.

Abstract: A tiered therapeutic reservoir of an ophthalmic device is described for controlled delivery of two or more therapeutic doses to a patient's eye. An ophthalmic device can include a reservoir having an interior and a metal electrode covering an opening of the reservoir. The interior of the reservoir can hold one or more pharmaceuticals or does of pharmaceuticals (referred to as drugs). The reservoir can hold a first drug and a second drug, with a sacrificial barrier layer positioned between the first drug and the second drug. The metal electrode can electrodissolve upon receiving an electrical signal to release the first drug from the reservoir. The sacrificial barrier layer can be sacrificed after the electrodissolution of the metal electrode to release the second drug from the reservoir. The first drug and the second drug can be released to an eye of a patient in contact with the ophthalmic device.

Abstract: Disclosed are methods of determining the suitability of a variable-length spectrophotometer using Patent Blue dye or AMG Blue dye. Also disclosed herein are methods of determining the suitability of a fixed path length spectrophotometer for determining protein concentration of a protein sample. AMG Blue dye may also be used to determine the suitability of fixed path length spectrophotometers.

Abstract: An ophthalmic device can be positioned on a surface of an eye and can modulate an amount of light that can be transmitted therethrough in response to environmental factors and/or release of a therapeutic agent into the eye. The ophthalmic device can include an electronically-mediated medium that can modulate an amount of light transmitted in response to a first electrical signal generated by a signal generator. The ophthalmic device also can include at least one drug reservoir that can release a therapeutic agent to the eye in response to a second electrical signal generated by the signal generator. The signal generator can be encapsulated within the ophthalmic device and in communication with a controller that defines parameters of the electrical signals generated by the signal generator.

Abstract: Systems, eye-mountable devices, and methods that facilitate chronotherapeutic treatment of primary open-angle glaucoma are provided which enable therapeutic products to be delivered to the eye in a controlled manner only when desired. According to one embodiment, an eye-mountable device comprises a substrate having an eye-mounting surface for positioning on an eye of a patient, a sensor that obtains a plurality of measurements representative of a condition of the eye of the patient over a period of time, a therapeutic agent delivery assembly coupled, and a processor for executing a temporal model of a therapeutic agent delivery in communication with the sensor and the therapeutic agent delivery assembly. The processor receives the plurality of measurements and activates the therapeutic agent delivery assembly to administer a first amount of a drug to the eye of the patient based on the temporal model associated with the plurality of measurements.

Abstract: A modular system can be used with commercial eyeglasses to interface with an electronic eye-mounted ocular device and used to control and/or actuate the electronic eye-mounted ocular device, exchange data with the electronic eye-mounted ocular device, and/or charge the electronic eye-mounted ocular device. The modular system includes an electroactive stick-on component attachable to a portion of an eyeglasses lens; and an electronic system attachable to an eyeglass frame in electrical communication with the electroactive stick-on component.

Abstract: A modular system can be used with commercial eyeglasses to deliver treatment for at least one ocular condition. The modular system includes an electroactive stick-on component attachable to a portion of an eyeglass lens; and an electronic system attachable to an eyeglass frame in electrical communication with the electroactive stick-on component.

Abstract: Systems, eye-mountable devices, and methods that facilitate chronotherapeutic treatment of primary open-angle glaucoma are provided which enable therapeutic products to be delivered to the eye in a controlled manner only when desired. According to one embodiment, an eye-mountable device comprises a substrate having an eye-mounting surface for positioning on an eye of a patient, a sensor that obtains a plurality of measurements representative of a condition of the eye of the patient over a period of time, a therapeutic agent delivery assembly coupled, and a processor for executing a temporal model of a therapeutic agent delivery in communication with the sensor and the therapeutic agent delivery assembly. The processor receives the plurality of measurements and activates the therapeutic agent delivery assembly to administer a first amount of a drug to the eye of the patient based on the temporal model associated with the plurality of measurements.

Abstract: An eye-mountable device is provided that includes an eyelid occlusion sensor. The eyelid occlusion sensor is used to detect winks, squints, downwards glances or looks, blinks, or other eye-based gestures generated by the user. Based on the detected gestures, an optical power of an adjustable lens of the device may be changed or some other operations could be performed by the eye-mountable device. Such operations could include toggling the optical power of the lens between first and second power levels due to the user squinting, looking downward, or performing some other gesture. Additionally or alternatively, such operations could include setting the optical power of the lens to a first optical power unless the user is looking downward, in which case the optical power of the lens could be set to a second optical power.

Abstract: Efficient electrochemical reactions can be achieved using a two-electrode system embedded within a silicone hydrogel by using a one-step linear sweep-hold method. A voltage value is initially set to be a voltage that corresponds to a peak current (Vp). An amperometric process is performed at the voltage value. During the amperometric process, the voltage value is corrected as a current shifts.

Abstract: An ophthalmic device including a hydrogel-based material body that can encapsulate a reservoir housing a therapeutic and a metal electrode covering the reservoir. The therapeutic can be delivered into an eye by way of electrodissolution of the metal electrode. The electrodissolution can be enhanced by the presence of chloride ions proximal to the metal electrode, and the ophthalmic device can be engineered to ensure the presence of chloride ions proximal to the metal electrode.

Abstract: The present disclosure relates to relates to systems and methods for on-demand delivery of a therapeutic agent from an eye mounted device. Particularly, aspects of the present invention are directed to a method of delivering a therapeutic agent, the method including receiving, at a controller of a therapeutic agent release and delivery device, a first command signal for delivery of a therapeutic agent based on a dosing time window. Upon receipt of the first command signal, the controller determines whether one or more compliance conditions are satisfied. When the one or more conditions are satisfied, the controller initiate a release and delivery protocol that commands a signal generator to generate and send a second command signal causing a capacitor or one or more circuits to deliver an actuation signal causing one or more therapeutic agent delivery mechanisms to open and release the therapeutic agent from one or more reservoirs.

Abstract: The present disclosure relates to devices and systems for targeted and controlled delivery of a therapeutic agent to a treatment site of an eye. Particularly, aspects are directed to a therapeutic agent delivery device that includes a polymeric substrate having a release region, a delivery region, and a receiving region; one or more reservoirs formed within the release region; a therapeutic agent disposed within the one or more reservoirs; an active, passive, or combination thereof controlled release mechanism for release of the therapeutic agent from the one or more reservoirs into the delivery region; and a circuit formed on the polymeric substrate, the circuit having a current source, a first iontophoresis electrode located within the delivery region for transport of the therapeutic agent from the delivery region into a target tissue via electromigration, and a second iontophoresis electrode located within the receiving region for maintaining electroneutrality within the tissue.